Q-omics provides the consensus-scored ARHGEF15 profile across patient tissues and cancer cell-line models. ARHGEF15 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGEF15 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, ARHGEF15 RNA expression shows 18,733 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, KIRP, and CCRCC as cancer lineages where ARHGEF15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGEF15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGEF15 survival associations across molecular data types. ARHGEF15 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGEF15 RNA expression–survival associations across cancer types. High ARHGEF15 expression shows unfavorable associations in KIRP, MESO and UVM, but favorable associations in KIRC, HNSC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGEF15 RNA expression.
This table summarizes ARHGEF15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARHGEF15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGEF15 shows lower tumor expression in KIRP, KICH, LUSC, LUAD and BLCA and higher tumor expression in KIRC. The KIRP box plot shows higher ARHGEF15 RNA expression in normal versus tumor tissue (log2 FC = −2.181, t-test p < 0.001).
This table shows molecular features associated with ARHGEF15 in patient tissues and cancer cell lines. In patient samples, ARHGEF15 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGEF15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
